Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | SETD2 | Q9BYW2 | 5/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21724782 | 0.88 | SETD2 (0.48) | CNR1KMT2AMAPTSETD2MEN1 | |
| SCHEMBL25039576 | 0.87 | SETD2 (0.53) | KMT2ASETD2MEN1NSD2 | |
| SCHEMBL26098096 | 0.84 | SETD2 (0.47) | KMT2AMAPTSETD2TRPV1MEN1 | |
| SCHEMBL26099783 | 0.82 | NPC1 (0.60) | KMT2AMAPTSETD2MEN1HTT | |
| SCHEMBL25039980 | 0.80 | CYP1A2 (0.57) | ALDH1A1KMT2AMAPTSETD2SMN1; SMN2 | |
| SCHEMBL17149667 | 0.77 | MAPT (0.50) | ALDH1A1KMT2AMAPTKDM4ETRPV1 | |
| SCHEMBL25039719 | 0.76 | SETD2 (0.57) | CNR1SETD2NSD2 | |
| SCHEMBL25040178 | 0.76 | SETD2 (0.59) | CNR1MAPTSETD2SMN1; SMN2MAPK1 | |
| SCHEMBL11733103 | 0.75 | ALDH1A1 (0.64) | CNR1ALDH1A1KMT2AMAPTKDM4E | |
| SCHEMBL25037735 | 0.73 | SETD2 (0.58) | CNR1MAPTSETD2MAPK1NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | Epizyme, Inc. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | SETD2, CARM1, SETDB1 | CNR1 4145/4885ALDH1A1 4158/4885KMT2A 24/4885 |
| US-20230049113-A1 | METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS BY INHIBITING SETD2 | NSD1, NSD3, EHMT1 | CNR1 4508/4885ALDH1A1 3592/4885KMT2A 33/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | CNR1 4321/4885ALDH1A1 4808/4885KMT2A 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.